載入...
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
Purpose: There is limited standard treatment for patients with advanced cholangiocarcinoma after refractory of chemotherapy. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2, which exhibited broad-spectrum antitumor activities in previous studies. We aim to evaluate the efficacy and safety...
Na minha lista:
| 發表在: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Ivyspring International Publisher
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7847639/ https://ncbi.nlm.nih.gov/pubmed/33532001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.53482 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|